Advertisement

An in vitro mouse macrophage model for use in assessing the effects of anti-inflammatory drugs

  • D. D. White
  • P. K. Fox
  • P. Livingston
Part of the Inflammation: Mechanisms and Treatment book series (FTIN, volume 4)

Abstract

Mononuclear phagocytic cells are implicated in many chronic inflammatory diseases1. In rheumatoid arthritis these cells, stimulated by inflammatory products, engulf immune complexes accumulating in the diseased joint, accompanied by a selective secretion of lysosomal acid hydrolases2. These have the capacity to activate complement and kinin pathways as well as inducing the destruction of the proteoglycan matrix of the joint3. Inhibition of the release of these hydrolases by lysosomal membrane stabilizing drugs may be an important means of reducing joint destruction in chronic arthritis3. Many anti-inflammatory drugs, e.g. hydrocortisone, dexamethasone, phenylbutazone and flufenamic acid, have been reported to stabilize lysosomal membranes4–6. With some of these compounds a correlation has been demonstrated between lysosomal stabilization effects in vitro and their antiinflammatory activities in vivo in animal models4.

Keywords

Lysosomal Enzyme Enzyme Release Flufenamic Acid Lysosomal Enzyme Activity Zymosan Particle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Loeui, G. (1975). Inflammatory arthritis: immunology and inflammation at the cellular level. In Holt, P. J. L. (ed.) Current Topics in Connective Tissue Diseases, p. 48. (London: Churchill-Livingstone)Google Scholar
  2. 2.
    Davies, P. and Allison, A. C. (1976). The macrophage as a secretory cell in chronic inflammation. Agents Actions, 6, 60PubMedCrossRefGoogle Scholar
  3. 3.
    Weissman, G. (1971). Lysosomes and the mediation of tissue injury in arthritis. In Muller, W., Harwerth, H. G. and Fehr, K. (eds.) Rheumatoid Arthritis, p. 141. (London: Academic Press)Google Scholar
  4. 4.
    Tanaka, K. and Iizuka, Y. (1968). Suppression of enzyme release from isolated rat liver lysosomes by non-steroidal anti-inflammatory drugs. Biochem. Pharmadol., 17, 2023CrossRefGoogle Scholar
  5. 5.
    Ringrose, P. S., Parr, M. A. and McLaren, M. (1975). Effects of anti-inflammatory and other compounds on the release of lysosomal enzymes from macrophages. Biochem. Pharmacol, 24, 607PubMedCrossRefGoogle Scholar
  6. 6.
    Smith, R. J. (1977). Phagocytic release of lysosomal enzymes from guinea-pig neutrophils-regulation by corticosteroids, autonomic neurohormones and cyclic nucleotides. Biochem. Pharmacol., 26, 2001PubMedCrossRefGoogle Scholar
  7. 7.
    Burkhardt, D., Stephens, R. S., Ghosh, P. and Taylor, T. K.F. (1978). Inhibition of synovial fluid lysosomal glycosidases by anti-arthritic gold preparations. Agents Actions, 8, 251PubMedCrossRefGoogle Scholar
  8. 8.
    Barrett, A. J. (1972). Lysosomal enzymes, In Dingle, J. T. (ed.) Lysosomes, a Laboratory Handbook. (Amsterdam: North-Holland Publishing)Google Scholar
  9. 9.
    Sigma Technical Bulletin No. 500. (1975). The quantitative colorimetric determination of lactate dehydrogenase. Sigma Chemical Co., St. LouisGoogle Scholar
  10. 10.
    Miller G. L. (1959). Protein determination for large numbers of samples. Anal. Chem., 31, 964CrossRefGoogle Scholar
  11. 11.
    Picton, W., Devitt H. and Forgie M. A. (1976). Practical applications of the Quantimet 720, an image analysing computer in the field of investigative dermatology. Br. J. Dermatol., 95, 341PubMedCrossRefGoogle Scholar
  12. 12.
    Walters, M. N.-I. and Papadimitriou, J. M. (1978). Phagocytosis; a review. CRC Crit. Rev. Toxicol, 5, 377PubMedCrossRefGoogle Scholar
  13. 13.
    Smith, R. J. (1979). The guinea-pig neutrophil calcium-dependent lysosomal enzyme secretory process. Inhibition by non-steroidal anti-inflammatory agents. Biochem. Pharmacol., 28, 2739PubMedCrossRefGoogle Scholar
  14. 14.
    Dean, R. T., Hylton, W. and Allison, A. S. (1979). Lysosomal enzyme secretion by macrophages during intracellular storage of particles. Biochem. Biophys. Acta, 584, 57PubMedCrossRefGoogle Scholar
  15. 15.
    Walz, D. T., Di Martino, M. J., Chakrin, L. W., Sutton, B. M. and Misher, A. (1976). Anti-arthritic properties and unique pharmacologic profile of a potential chrysotherapeutic. Agent, S.K.&F. D-39162. J. Pharmacol. Exp. Ther., 197, 142PubMedGoogle Scholar
  16. 16.
    Finklestein, A.E., Walz, D.T., Batista, V., Mizraji, F., Roisman, F., and Misher, A. (1976). Auranofin. A new oral gold compound for treatment of rheumatoid arthritis. Ann. Rheum. Dis., 35, 251CrossRefGoogle Scholar
  17. 17.
    Berglöf, F-E., Berglöf, K. and Walz, D.T. (1978). Auranofin; an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J. Rheumatol, 5, 68PubMedGoogle Scholar

Copyright information

© MTP Press Limited 1980

Authors and Affiliations

  • D. D. White
    • 1
  • P. K. Fox
    • 1
  • P. Livingston
    • 1
  1. 1.UK

Personalised recommendations